Genmab — Maj 2019

[Bulder]

Vil det sige, at de har droppet cd40x4-1bb? Carlsen var fortrøstningsfuld så sent som Q&A.

[Bulder]

Måske bare forsinket, så de har pillet den af fact sheet, hjemmeside og CT.

[Bulder]

Den er stadig nævnt på fact sheet i højre side.

[Bulder]

https://ir.genmab.com/static-files/2541bd13-afb9-4c9d-91c4-7ec4c3b0fdc6

[ROI_-_David_Mygind]

For dem der hænger ud på chatten på en høj-hellig dag som i dag er her et sneak peak på noget jeg roder lidt med: http://bit.ly/genmab-industry-dynamics

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

Torben Plesner : " I continue with daratumumab monotherapy as a maintenance strategy "forever" " https://twitter.com/MM_Hub/status/1129414362874163200

[E_L]

i think maybe i should repeat an earlier link nobody reacted to

[E_L]

2/5 10:19
af E L
Usmani - Daratumumab as Frontline Treatment for Multiple Myeloma - https://www.youtube.com/playlist?list=PLZRBUfZtYYA9r0cx7Qo2psrJ9wi2sJg7A

[E_L]

2/5 12:35
af E L
Do I understand this correct, from Usmani video 3, that the Lenalidomide dosing in the experimental arm turned out to be 76% of the dosing of the standard care arm

[E_L]

Ola Landgren, M.D.
@DrOlaLandgren

https://twitter.com/DrOlaLandgren/status/1129544139215912960

[E_L]

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32178

[E_L]

A Multiple Myeloma Roundtable: Treatment Trends and Recent Clinical Advances http://obroncology.com/article/a-multiple-myeloma-roundtable-treatment-trends-and-recent-clinical-advances/#

[Bulder]

Yes, they have reduced dose of len more frequently in the exp-arm than in soc-arm. They have also done this earlier with pom. At least in the first cycle or two. I suppose it is due to side effects.

[Helge_LarsenPI-redaktør]

Lad os endelig for mere af dette her: http://www.proinvestor.com/investornyt/617848/her-er-ugens-vindere-og-tabere-alk-netcompany-og-genmab-topper

[Bulder]

What does Plesner mean by: ... "but the results may be further improved"?

[E_L]

Autologous Stem Cell Transplantation Challenged by Emerging Pharmacotherapies in Multiple Myeloma https://www.hematologyadvisor.com/home/topics/myeloma/evaluating-the-viability-of-pharmacotherapies-as-an-alternative-to-transplant-in-multiple-myeloma/

[E_L]

yea, read that too... maybe improved OS or HR?

[Bulder]

Landgren's statement is interesting: "No IRRs. Minimal or no steroids/premeds." That could be the reason for dara's recurrence in solids.

[E_L]

good point. that could be the key if we think about the JNJ presentation, where they said that " they are developping a 'steroid sparing regimen' to be used with Dara and they indeed needed SC to do that"